Who
Kyle Piskel
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Adaptive Biotechnologies.
In numbers
- Trades disclosed
- 50
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $4.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Nov 2021
- Last trade
- 18 May 2026
- Last filed
- 20 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 May 2026filed 20 May 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $41K3,115 at $13.04 | filing |
| 18 May 2026filed 20 May 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $41K3,115 at $13.04 | filing |
| 11 Mar 2026filed 13 Mar 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $246K18,672 at $13.17 | filing |
| 11 Mar 2026filed 13 Mar 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $246K18,672 at $13.17 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Code A | —61,875 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Code A | —61,875 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Code M | $26K2,145 at $12.14 | filing |
| 4 Feb 2026filed 6 Feb 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $40K2,145 at $18.46 | filing |
| 4 Feb 2026filed 6 Feb 2026 | ADPT Adaptive Biotechnologiesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —2,145 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | ADPT Adaptive Biotechnologiesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —2,145 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Code M | $26K2,145 at $12.14 | filing |
| 4 Feb 2026filed 6 Feb 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $40K2,145 at $18.46 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Code M | $52K4,290 at $12.14 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $77K4,290 at $18.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ADPT Adaptive Biotechnologiesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —4,290 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ADPT Adaptive Biotechnologiesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —4,290 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Code M | $52K4,290 at $12.14 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $77K4,290 at $18.00 | filing |
| 28 Nov 2025filed 2 Dec 2025 | ADPT Adaptive Biotechnologiesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —11,980 at $0.00 | filing |
| 28 Nov 2025filed 2 Dec 2025 | ADPT Adaptive Biotechnologiesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
News
Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 11,881 Shares of Company StockADPT · dailypolitical.com · 21 Oct 2026
0 headlines in the last 90 days name Kyle Piskel; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.